What is the recommended dosing for memantine (Namenda) augmentation for Obsessive-Compulsive Disorder (OCD) in a patient with bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), and current medications including Vraylar (cariprazine) 3mg, Lamictal (lamotrigine) 350mg, Concerta (methylphenidate) 27mg, Zepbound (ziprasidone) 5mg, and propranolol 20mg daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Memantine Dosing for OCD Augmentation

Start memantine at 5mg daily for one week, then increase to 10mg daily for one week, followed by a target dose of 20mg daily for OCD augmentation. 1, 2

Dosing Protocol

Initial titration schedule:

  • Week 1: 5mg once daily
  • Week 2: 10mg once daily
  • Week 3 onward: 20mg once daily (target dose) 2

This gradual titration minimizes side effects while achieving the therapeutic dose demonstrated in clinical trials. 2

Evidence Base and Positioning

Memantine is a third-line augmentation option for treatment-resistant OCD, recommended only after you have optimized SSRI dose and duration, tried switching to another SSRI or clomipramine, attempted antipsychotic augmentation (risperidone or aripiprazole), and considered N-acetylcysteine. 1

The evidence for memantine is mixed and controversial:

  • One double-blind RCT showed 89% remission rates with memantine augmentation versus 32% with placebo when added to fluvoxamine at 20mg daily. 2
  • However, a critical 2019 analysis found that all four RCTs supporting memantine came from the same geographical area and presented completer analyses rather than intention-to-treat data, significantly compromising validity. 3
  • The meta-analysis showing very large benefits (81% response vs 19% placebo) cannot be considered sound due to these methodological concerns. 3

Despite these limitations, memantine has demonstrated efficacy in several trials and can be considered in clinical practice given its favorable safety profile. 1, 4

Critical Considerations for Your Patient

Drug interaction concerns:

  • Memantine has no significant interactions with Vraylar (cariprazine), Concerta (methylphenidate), Zepbound (tirzepatide), or propranolol. 1
  • Important caveat: One case series reported lamotrigine-induced OCD in bipolar patients, with symptoms developing 2-8 months after lamotrigine initiation. 5 Your patient on Lamictal 350mg may have lamotrigine-contributing to OCD symptoms, though this is rare and controversial.

Monitoring requirements:

  • Memantine has minimal metabolic side effects compared to antipsychotic augmentation, requiring no routine laboratory monitoring. 6, 1
  • Watch for dizziness, headache, and confusion during titration. 2

Alternative Strategies with Stronger Evidence

Before adding memantine, ensure you have:

  • Confirmed adequate SSRI trial (maximum tolerated dose for 8-12 weeks with documented adherence) 7
  • Added or optimized Cognitive Behavioral Therapy with Exposure and Response Prevention (ERP), which has larger effect sizes than any pharmacological augmentation. 7, 6

If memantine fails or is not tolerated:

  • N-acetylcysteine has stronger evidence (3 out of 5 RCTs positive) with doses of 1200-2400mg daily. 7, 6
  • Deep rTMS is FDA-approved for treatment-resistant OCD with moderate effect size (0.65) and 3-fold increased response versus sham. 7, 6

Treatment Duration

Maintain memantine for at least 8 weeks to assess response, and if effective, continue for 12-24 months after achieving remission due to high OCD relapse rates. 7

References

Guideline

Memantine Augmentation for Treatment-Resistant OCD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Augmentation With Memantine in Obsessive-Compulsive Disorder.

The Journal of clinical psychiatry, 2019

Research

The use of memantine in neuropsychiatric disorders: An overview.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2018

Guideline

Limitations of Risperidone in Treatment-Resistant Obsessive-Compulsive Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Treatment of Treatment-Resistant OCD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Is Namenda (memantine) used to treat Obsessive-Compulsive Disorder (OCD)?
What is the recommended dose of memantine (N-methyl-D-aspartate (NMDA) receptor antagonist) for the treatment of Obsessive-Compulsive Disorder (OCD)?
Can memantine augmentation address symptoms of brain fog, anhedonia, fatigue, sexual side effects, and obsessive-compulsive disorder (OCD) in a patient with a complex psychiatric history, currently taking selective serotonin reuptake inhibitors (SSRIs) like sertraline?
Can adding memantine, buspirone, or N-acetylcysteine (NAC) be an alternative to aid social flatness in a patient sensitive to stimulants and their side effects, particularly with obsessive-compulsive disorder (OCD) and mood dysregulation, instead of discontinuing viloxazine (serotonin-norepinephrine reuptake inhibitor)?
What are the potential benefits and risks of adding memantine to a regimen of sertraline, guanfacine (extended release), and viloxazine in a patient with obsessive-compulsive disorder (OCD) and a history of adverse reactions to bupropion, escitalopram, and vilazodone?
When is shingles considered healed in a patient with a typical infection?
What are the key considerations for counseling a patient with type 2 diabetes about initiating Mounjaro (tirzepatide) therapy?
What is Guillain-Barré Syndrome (GBS), its causes, symptoms, treatment options, and prognosis in adults?
What is the recommended management approach for an adolescent experiencing anxiety and depression?
What is the role of gabapentin (Neurontin) in treating hyperphosphatemia-induced pruritus in a patient with End-Stage Renal Disease (ESRD)?
Is Pristiq (desvenlafaxine) safe to use during pregnancy for a female patient with a history of depression or anxiety?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.